|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Allergan Inc. (AGN) Seeks Sale of Obesity Biz by First Quarter
1/8/2013 8:23:21 AM
Allergan Inc. (AGN), the maker of the Botox wrinkle treatment, has attracted interest for its weight- loss unit and wants to sell the business by the end of the first quarter, Chief Executive Officer David Pyott said. Allergan said in October it would consider a sale of the obesity business, including the Lap-Band device, as revenue declined and concerns rose about the weight-loss procedure. “There’s a lot of interest, some strategic companies, but especially in terms of numbers, private equity players,” Pyott said yesterday in an interview at the annual health-care conference sponsored by JPMorgan Chase & Co. (JPM) in San Francisco. “Sometime in the first quarter this will come to pass.” Allergan in November said it would buy a unit of SkinMedica Inc. for $350 million to expand its skin-care business. Botox, with about $1.6 billion in 2011 sales, is the Irvine, California-based company’s best seller. Revenue for the obesity intervention unit will be about $160 million in 2012, the company said in a statement in October. Sales declined from $203.1 million last year and a peak of $296 million in 2008, the company reported.
|
|
|
|
|
|
|
|
|
|
|